CDC logo Tuberculosis Information CD-ROM   Image of people
   
1
spacer image

Table 1. Regimen Options for Treatment of Latent TB Infection in HIV-Negative Persons, 2000

Updated August 2003
Drug Regimens Comments
Daily Twice Weekly
Children/
Duration
Adults/
Duration
Children/
Duration
Adults/
Duration
INH 9 months 9 months 9 months 9 months

Preferred regimen

Minimum of 270 doses administered within 12 months

Twice-weekly regimens should consist of at least 76 doses administered within 12 months.

Recommended regimen for pregnant women

Contraindicated for persons who have active hepatitis and end-stage liver disease

INH Not recommended 6 months Not recommended 6 months

Minimum of 180 doses administered within 9 months

Twice-weekly regimens should consist of at least 52 doses within 9 months.

Not recommended for those with fibrotic lesions on chest radiographs or children

Contraindicated for persons who have active hepatitis and end-stage liver disease

RIF
4 months 4 months

Not recommended

Minimum of 120 doses administered within 6 months

For patients who likely have INH-resistant, RIF-susceptible LTBI

Acceptable alternative; may be used for patients who cannot tolerate INH

RIF and PZA

 

Should generally not be offered

A TB/LTBI expert should be consulted prior to the use of this regimen.

Footnotes

INH - isoniazid, RIF- rifampin, PZA - pyrazinamide, EMB - ethambutol; LTBI - latent TB infection

Directly observed treatment of LTBI should be used.

 


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination - http://www.cdc.gov/tb

Please send comments/suggestions/requests to: hsttbwebteam@cdc.gov, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333